{
  "study_id": "NCT00973609",
  "study_title": "Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial",
  "table_name": "Baseline Characteristics",
  "table_title": "Baseline Patient Characteristics",
  "description": "The provided document is an abstract of the clinical trial publication and does not contain a table with baseline demographics. The group information has been extracted from the text in the 'Findings' section.",
  "footnotes": [],
  "groups": [
    {
      "name": "fluoropyrimidine plus bevacizumab",
      "n": 158,
      "type": "intervention"
    },
    {
      "name": "bevacizumab monotherapy",
      "n": 156,
      "type": "intervention"
    },
    {
      "name": "no treatment",
      "n": 158,
      "type": "control"
    }
  ],
  "characteristics": []
}